Last reviewed · How we verify
NCT05691660
A Study of TAS3731 in Healthy Adults
Phase 1 trial testing TAS3731 Dose1 in Healthy Adult Males in 238 participants. Completed in 21 May 2024.
21 May 2024
Quick facts
| Lead sponsor | Taiho Pharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 238 |
| Start date | 17 January 2023 |
| Primary completion | 21 May 2024 |
| Estimated completion | 21 May 2024 |
| Sites | 1 location across Japan |
Drugs / interventions tested
- TAS3731 Dose1 — full drug profile →
- TAS3731 Dose2
- TAS3731 Dose3
- Placebo
- Placebo
- Placebo
Conditions studied
- Healthy Adult Males — all drugs for Healthy Adult Males →
Sponsor
Taiho Pharmaceutical Co., Ltd. — full company profile →
Who can join
Adults 18 to 39, male only, with Healthy Adult Males. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the safety of single and repeated administration of TAS3731.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05691660
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Taiho Pharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT05621447 — A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects · Phase 1 · completed
- NCT05335499 — A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria · Phase 2 · completed
- NCT04825431 — Mass Balance Study of [14C] TAS-205 in Healthy Volunteers · Phase 1 · completed
- NCT04512053 — A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence · Phase 2 · completed
- NCT03605251 — Efficacy and Safety Study of TAS5315 Compared With Placebo in Participants With Rheumatoid Arthritis. · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05691660 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Taiho Pharmaceutical Co., Ltd.
- Last refreshed: 14 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05691660.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing